Pharmaceuticals - Gambia

Gambia

In 2024, the projected revenue in the Pharmaceuticals market in Gambia is expected to reach US$18.52m.
The largest market within this market is Oncology Drugs, with a projected market volume of US$0.95m in 2024.
Looking ahead, the market is anticipated to display an annual growth rate (CAGR 2024-2029) of -8.19%, resulting in a market volume of US$12.08m by 2029.
When compared globally, United States is forecasted to generate the highest revenue, amounting to US$630.30bn in 2024.
The pharmaceutical market in Gambia is experiencing a surge in demand for traditional herbal medicines.

Key regions: United States, China, Germany, Japan, Europe

Definition:
The Pharmaceuticals market covers remedies used to cure, treat, prevent, and diagnose diseases. These small molecule drugs or biologic medical products may be called drugs, medications, or medicines. Prescription drugs and over-the-counter (OTC) drugs are both included. Depending on the regulations in each country, these products are provided by pharmacies, hospitals, physicians, and/or drug stores, and/or they can be bought elsewhere. They may be administered in the form of pills, capsules, gels, ointments, injections, infusions, lozenges, or aerosols/sprays.

Structure:
The market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Antiviral Drugs, Immunosuppressants, Bronchodilator Drugs, Sensory Organ Drugs, Anti-Hypertensive Drugs, Anti-Coagulants, Anti-Fibrinolytic Drugs, Multiple Sclerosis Drugs, Lipid-Lowering Agents and Other Pharmaceuticals. The Pharmaceuticals market is organized in markets that cover drugs used in specific medical fields, i.e., medicines for a specific disesase or a certain type of medicine. They include original brands, biosimilars, generics, and orphan drugs.The Oncology Drugs market covers pharmaceutical products specifically developed for the treatment and management of various cancers. The Anti-Diabetes Drugs market covers medications designed to manage blood glucose levels and improve insulin sensitivity in individuals with diabetes. The market Anti-Rheumatic Drugs includes pharmaceuticals specifically developed to alleviate symptoms, reduce inflammation, and modify the progression of rheumatic diseases. The Dermatological Drugs market covers pharmaceuticals formulated to treat and manage a wide range of skin conditions such as eczema, acne, and rosacea. The Antiviral Drugs market includes medications designed to treat viral infections and reducing the severity and duration of symptoms. The Immunosuppressants market covers pharmaceuticals that suppress the immune system's activity. The Bronchodilator Drugs market covers pharmaceuticals designed to relax and widen the airways in the lungs. The Sensory Organ Drugs market covers pharmaceuticals targeting the treatment of disorders and conditions affecting sensory organs such as the eyes, ears and nose. The Anti-hypertensive Drugs market covers pharmaceuticals designed to lower blood pressure levels. The Anti-Coagulants Drugs market covers pharmaceuticals developed to prevent the formation of blood clots or to dissolve existing clots. The Anti-Fibrinolytics Drugs market covers pharmaceuticals designed to inhibit the breakdown of blood clots. The Multiple Sclerosis Drugs market covers pharmaceuticals aimed at managing and modifying the course of multiple sclerosis. The Lipid-Lowering Agents market covers pharmaceuticals developed to reduce levels of cholesterol and other lipids in the blood. The Other Pharmaceuticals market provides information on additional specialties that are not covered by the main markets.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Roche, Pfizer, Merck & Co, Johnson & Johnson, AbbVie, Sanofi.

Market

Region

Region comparison

Currency

Analyst Opinion

The Pharmaceuticals market in Gambia is showing promising growth in recent years.

Customer preferences: The demand for pharmaceutical products in Gambia is driven by the need for affordable and accessible healthcare services. Customers in Gambia are increasingly seeking out quality medicines that are effective in treating their health conditions. As a result, there is a growing demand for both generic and branded pharmaceutical products in the market.

Trends in the market: The pharmaceuticals market in Gambia has been growing steadily in recent years. One of the key drivers of this growth is the increasing investment in the healthcare sector by the government. This has led to the expansion of healthcare facilities and the improvement of healthcare services in the country. Additionally, the rise in the prevalence of chronic diseases such as diabetes and hypertension has led to an increase in demand for pharmaceutical products.

Local special circumstances: One of the major challenges facing the pharmaceuticals market in Gambia is the lack of local manufacturing capacity. As a result, most of the pharmaceutical products in the market are imported from other countries. This makes the market vulnerable to supply chain disruptions and price fluctuations. However, there is increasing interest in the establishment of local pharmaceutical manufacturing facilities in the country, which could help to address these challenges.

Underlying macroeconomic factors: The growth of the pharmaceuticals market in Gambia is closely linked to the overall economic development of the country. The government's efforts to improve the business climate and attract foreign investment have helped to create a more favorable environment for pharmaceutical companies. Additionally, the country's young and growing population presents a significant market opportunity for pharmaceutical companies looking to expand their operations in the region.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.